Lhasa Limited shared knowledge shared progress

Can public data improve mutagenicity predictions for proprietary compounds.pdf

pdf fileBarber CG; Williams RV;

It has long been axiomatic that predictive toxicology models built on data available in the public domain can encounter problems when attempting to predict proprietary data, e.g. from a drug development program. Conversely, model performance against public data is often used to support the selection of models for specific applications and such analyses are often published. One outcome of some recent model development work has been to produce metrics that can be used to experimentally test the axiom and assess the validity of basing conclusions on public data.

Presented by Chris Barber at SOT, Phoenix, USA; 24th March 2014.


© 2019 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.